Journal of Neurology Neurosurgery & Psychiatry · 1981 · 166 citations · 9 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyMovement DisordersNeuropharmacologyNeurodegenerative Disease PharmacotherapyParkinson DiseaseParkinsonian DisordersBromocriptine TreatmentLate ComplicationsLate-onset ComplicationsMaximum Tolerated EffectParkinson's Disease PharmacotherapyParkinson’s Disease PharmacotherapyParkinson’s Disease TreatmentSustained Improvement
The progress of 50 previously untreated patients with idiopathic Parkinson's disease taking maximum tolerated doses of bromocriptine is compared with patients who had taken levodopa. Twenty-eight of the bromocriptine treated patients showed sustained benefit for at least one year and in five this persisted longer than five years. Fewer of the late complications of levodopa therapy occurred in those taking bromocriptine; drug-induced dyskinesia was seen in only one patient and oscillations in performance were not observed. There was a tendency for deterioration to develop after two years treatment when patients then failed to respond well to levodopa. It was not possible to extend the period of effective control of disabilities by first giving bromocriptine.
9
Margaret M. Hoehn, Melvin D. Yahr · Neurology · 1967 · 12K citations · Full text
Overdependence on degraded gist memory in Alzheimer's disease.
Neuropsychology · 2006 · 4.7K citations
Critical analysis of the disability in Parkinson's disease.
David D. Webster · PubMed · 1968 · 490 citations
Medicine, Neurology, Neuroscience +12
LONG-TERM TREATMENT OF PARKINSONISM WITH BROMOCRIPTINE
DonaldB Calne, AdrianC Williams, Andreas Neophytides et al. · The Lancet · 1978 · 135 citations